199102-71-1 Usage
Uses
Used in Organic Synthesis:
ω-cyano-4-isopropoxy-3-methoxyacetophenone is used as a building block for the synthesis of various organic compounds, contributing to the development of new chemical entities.
Used in Pharmaceutical Production:
ω-cyano-4-isopropoxy-3-methoxyacetophenone is employed as a precursor in the production of pharmaceuticals, leveraging its biological activities to contribute to the creation of potential therapeutic agents.
Used in Agrochemical Production:
ω-cyano-4-isopropoxy-3-methoxyacetophenone is used as a starting material in the synthesis of agrochemicals, with its antimicrobial properties being particularly beneficial in this application.
Used in Material Science:
ω-cyano-4-isopropoxy-3-methoxyacetophenone has been studied for its potential applications in the development of new materials, indicating its utility in advancing material technologies.
Used in Drug Delivery Systems:
ω-cyano-4-isopropoxy-3-methoxyacetophenone is being explored for its use in drug delivery systems, where its properties may enhance the delivery and efficacy of therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 199102-71-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,9,1,0 and 2 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 199102-71:
(8*1)+(7*9)+(6*9)+(5*1)+(4*0)+(3*2)+(2*7)+(1*1)=151
151 % 10 = 1
So 199102-71-1 is a valid CAS Registry Number.
199102-71-1Relevant academic research and scientific papers
Thienopyridine derivatives and their use
-
, (2008/06/13)
PCT No. PCT/JP97/01413 Sec. 371 Date Jun. 26, 1997 Sec. 102(e) Date Jun. 26, 1997 PCT Filed Apr. 23, 1997 PCT Pub. No. WO97/40050 PCT Pub. Date Oct. 30, 1997There is disclosed a compound of the formula (A): wherein W is C-G or C-G' (G is optionally esterified carboxyl; and G' is halogen); X is oxygen, optionally oxidized sulfur or -(CH2)q- (q is 0 to 5); R is optionally substituted amino or heterocyclic group; the ring B is optionally substituted nitrogen-containing 5- to 7-membered ring; L is hydrogen, optionally substituted hydrocarbon residue, optionally substituted acyl, optionally substituted carbamoyl, optionally substituted thiocarbamoyl or optionally substituted sulfonyl provided that, when W is C-G, L is hydrogen, optionally substituted acyl, optionally substituted carbamoyl, optionally substituted alkoxycarbonyl, optionally substituted thiocarbamoyl or optionally substituted sulfonyl; n is 0 or 1; the ring A may have a substituent. A process for producing the compound (A) and a pharmaceutical composition containing the compound (A) are also disclosed. The pharmaceutical composition is useful for an anti-inflammatory drug, particularly, a drug for preventing or treating arthritis, a drug for inhibiting bone resorption, immunosuppressant or the like.
